Caterina Lanna

19PUBLICATIONS
22CO-AUTHORS
Gene and molecular therapyAutoimmunityAllergyImmunogenetics (incl. genetic immunology)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 15, 2025
Tildrakizumab 200 mg: a step forward in psoriasis treatment with added metabolic benefits.

Caterina Lanna, Antonia Rivieccio, Chiara Cattani

|Feb 10, 2025
Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics.

E Mortato, F Artosi, C Borselli

|Oct 10, 2024
Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series.

Enrico Matteini, Laura Diluvio, Sara Lambiase

|Oct 03, 2022
Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology.

Caterina Lanna, Sara Lambiase, Ruslana Gaeta Shumak

|Apr 18, 2022
Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study.

Virginia Garofalo, Francesco Geraci, Monia Di Prete

|Feb 09, 2022
Coesisting inflammatory skin diseases: Tildrakizumab to control psoriasis and omalizumab for urticaria.

Laura Diluvio, Chiara Pensa, Arianna Piccolo

Pageof 4

Frequent Collaborators

9 joint publications

Elena Campione

5 joint publications

Terenzio Cosio

4 joint publications

Luca Bianchi

3 joint publications

Sara Mazzilli